🔥 A Two-Target Cancer Drug Just Cut Lung-Cancer Progression Risk by 60%

When your lung cancer stops responding to the pill that was keeping it in check, your next option has usually been chemotherapy — and chemo, in this setting, buys you a little under six months before the disease starts moving again. That has been the grim arithmetic for years.

A drug called izalontamab brengitecan — “iza-bren,” mercifully — just rewrote it. In a Phase 3 trial, patients taking iza-bren went a median 11.1 months before their cancer progressed, versus 5.7 months on chemo (OncLive). That is nearly double the time, and it translates into a 60% reduction in the risk of progression or death (hazard ratio 0.40).

The results landed at the ESMO cancer congress in Madrid on October 26 and were published the same day in The Lancet (Bristol Myers Squibb / SystImmune, via biopharminternational).

The thesis is simple: for a group of patients who had genuinely run out of good moves, a drug that hits two targets at once just beat the standard of care by a margin that is hard to argue with.

🧠 Why This Matters

The patients in this trial, called PANKU-Lung01, all had EGFR-mutated non-small cell lung cancer — the most common genetic flavor of the disease in non-smokers and younger patients. For years, the playbook has worked well at first: a targeted pill (a third-generation EGFR inhibitor like osimertinib) can hold the cancer back for a year or two. Then the tumor evolves, the pill stops working, and the options collapse to chemotherapy.

So this trial is set at the exact moment when things usually go wrong. These are people whose cancer already outsmarted the best targeted drug available. Beating chemo here, in that spot, is the whole point. 11.1 months versus 5.7 is not a rounding error — it is roughly an extra five months before the scan shows the cancer on the move again.

📊 Deep Dive

Iza-bren is what’s called a bispecific antibody-drug conjugate. Picture a guided missile with two homing sensors instead of one: the antibody locks onto both EGFR and HER3 — two proteins studded across these tumor cells — and once it docks, a cleavable linker releases a topoisomerase I inhibitor, a chemotherapy payload, directly into the cancer cell. Two targets mean more ways to grab the tumor and fewer easy escape routes.

The numbers from the prespecified interim analysis, head to head against platinum chemotherapy:

• Median progression-free survival: 11.1 months (iza-bren) vs 5.7 months (chemo)
• Risk of progression or death: cut by 60% — hazard ratio 0.40 (95% CI 0.31–0.51; p<0.0001)
• Confirmed objective response rate: 60.2% of patients responded on iza-bren vs 34.5% on chemo
• Median duration of response: 10.4 months vs 5.7 months
• Trial size: 422 patients treated — 216 on iza-bren, 206 on chemotherapy (OncLive)

The response rate is the line that jumps out. Six in ten patients saw their tumors shrink on iza-bren, against roughly one in three on chemo. And when they responded, the response lasted close to twice as long.

“These results support iza-bren as a promising new treatment option” for EGFR-mutant lung cancer after TKI resistance. — Li Zhang, MD, Sun Yat-sen University Cancer Center, presenting the data at ESMO 2026

⚠️ The Catch

Here is the number that is not on the scoreboard yet: overall survival. Progression-free survival tells you how long the cancer stays quiet; it does not, by itself, tell you whether patients live longer. In PANKU-Lung01 the survival data are still immature — the companies report a favorable trend, but a survival benefit has not been established (biopharminternational). Until that readout matures, the headline stays “delays the cancer,” not “extends life.”

Two more caveats worth holding onto. This interim analysis had a median follow-up of 14.6 months, so these are early numbers that could shift. And ADCs carrying a topoisomerase payload come with real side-effect profiles; the full safety picture matters as much as the efficacy once this reaches everyday clinics.

🎯 What Happens Next

The Lancet publication and the late-breaking ESMO slot are the setup for the part that actually changes patient care: regulatory filings. A hazard ratio of 0.40 against the standard of care is the kind of result that drug regulators take seriously, and iza-bren is already being pushed across multiple cancer types, not just lung.

Watch for the overall-survival update — that is the readout that decides whether iza-bren becomes a new default or just a strong option. And watch the breast-cancer and other solid-tumor programs built on the same molecule, because a two-target ADC that works this well in lung rarely stays confined to one disease.

🧩 Bigger Picture

There is a business story sitting underneath the clinical one. Iza-bren didn’t start inside a US pharma giant. It was discovered by Sichuan Biokin Pharmaceutical, and its US-based affiliate SystImmune out-licensed it to Bristol Myers Squibb in December 2023 in a deal worth $800 million upfront and up to $8.4 billion in total potential value (pharmalive). SystImmune keeps the rights in mainland China; BMS develops and commercializes it elsewhere.

That structure — a Chinese-originated molecule licensed by a Western drugmaker for billions — has become one of the defining patterns in oncology dealmaking. The ADC pipeline flowing out of Chinese labs is large, and buyers in the US and Europe have been writing some of the biggest checks in the industry to secure the best of it. PANKU-Lung01 is the kind of data that tells those buyers whether the checks were worth it.

“Dual-targeting EGFR and HER3 may fundamentally shift outcomes for these patients.” — Jonathan Cheng, MD, Chief Medical Officer, SystImmune

For the patient staring at a scan after their targeted pill quit, the plumbing of the deal is irrelevant. The number that matters is eleven months instead of six — and this week, that number is real, peer-reviewed, and sitting in The Lancet.

Chemo held the line for six months. A drug with two heads just about doubled it — now it has to prove the bigger promise: not just a longer pause, but a longer life.

---

Sources

• OncLive — Iza-Bren Improves PFS vs Platinum Chemo in EGFR-Mutated NSCLC After Third-Generation TKI
• biopharminternational — BMS, SystImmune Report Phase 3 PFS Data for Iza-Bren in EGFR NSCLC
• pharmalive — BMS inks potential $8.4B deal for SystImmune’s ADC for lung, breast cancer

❓ Quick answers

How well did iza-bren work in the PANKU-Lung01 lung cancer trial?

It extended median progression-free survival to 11.1 months versus 5.7 months on chemotherapy, a 60% reduction in progression risk (hazard ratio 0.40), per data published in The Lancet on October 26, 2026.

What is iza-bren (izalontamab brengitecan)?

It is a bispecific antibody-drug conjugate that targets both EGFR and HER3 and delivers a topoisomerase I inhibitor payload. It was developed by Sichuan Biokin/SystImmune and licensed to Bristol Myers Squibb in a December 2023 deal worth up to $8.4 billion.

Does iza-bren help lung cancer patients live longer?

Not proven yet. As of the October 2026 ESMO readout, overall-survival data were still immature with only a favorable trend reported; the confirmed benefit so far is delayed cancer progression, not extended survival.